No image available for this title

LITERATURE

Remdesivir: First Approval


The antiviral agent remdesivir (Veklury®; Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity
against viruses from several families. Having demonstrated potent antiviral activity against coronaviruses in preclinical studies, remdesivir emerged as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, during the current global
pandemic. Phase III evaluation of remdesivir in the treatment of COVID-19 commenced in early 2020 and has thus
far yielded promising results. In late May 2020, Taiwan conditionally approved the use of remdesivir in patients with
severe COVID-19.


Availability

Jubi-R-004Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
-
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous